The human nasal mucous membrane during chronic inflammation, before and after muco-active therapy: a study using scanning electron microscopy.
Chronic inflammation seems to induce alterations in nasal mucosa morphology. The type and extent of these alterations seem to be directly correlated with the duration of the inflammation. This study was carried out to ascertain whether the administration of muco-active drugs could modify these alterations by inducing their total or partial regression. Ten healthy control subjects, and thirty patients affected with chronic rhinopharyngitis, at various levels of severity, were studied. All the forty subjects underwent biopsy of the posterior region of the medium turbinate. The bioptic samples were examined using Scanning Electron Microscopy (SEM). Patients with phlogosis underwent treatment which consisted of a single day administration of carbocysteine-sobrerol (1125 mg carbocysteine and 180 mg sobrerol day 20 days). This group underwent biopsy again and the fragments obtained were studied using the same method. Chronic inflammation, in the nasal epithelium, causes progressive degenerative phenomena, which are related to the duration and to the severity of the pathology. The response of the nasal mucosa principally results in damage to the muco- ciliary unit, loss of cilia and consistent modifications in the mucous secretion. In cases of persistent inflammation, the nasal epithelium becomes squamous. The therapy employed was able to alter the morphological signs of degeneration in the less severe cases, and to improve the overall pattern of the most severe and irreversible pathologies.
Pacini
P
P
Dipartimento di Anatomia Umana, Università di Firenze.
Gulisano
M
M
Dallai
S
S
Polli
G
G
Gheri
G
G
D000328:Adult; D001706:Biopsy; D002233:Carbocysteine / Q000627:therapeutic use; D002908:Chronic Disease; D005100:Expectorants / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008855:Microscopy, Electron, Scanning; D008875:Middle Aged; D009297:Nasal Mucosa / Q000473:pathology*; D009304:Nasopharyngitis / Q000188:drug therapy / Q000473:pathology*; D012720:Severity of Illness Index; D013729:Terpenes / Q000627:therapeutic use
D005100:Expectorants; D013729:Terpenes; D002233:Carbocysteine; C003316:sobrerol